CC-223 inhibits human head and neck squamous cell carcinoma cell growth

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aberrant mTOR signaling is implicated in head and neck squamous cell carcinoma (HNSCC) progression.
• Targeting the mTOR pathway presents a potential therapeutic strategy for HNSCC.

Purpose of the Study:

• To investigate the efficacy of CC-223, a novel mTOR kinase inhibitor, against human HNSCC cells.
• To evaluate the in vitro and in vivo anti-cancer activity of CC-223 in HNSCC models.

Main Methods:

• Treatment of SCC-9 and primary oral cavity carcinoma (OCC) cells with CC-223.
• Assessment of cell survival, proliferation, cell cycle, and apoptosis.
• Evaluation of mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) activation.
• In vivo studies using SCC-9 xenografts in immunodeficient mice.

Main Results:

• CC-223 significantly inhibited HNSCC cell survival, proliferation, and cell cycle progression at nanomolar concentrations.
• CC-223 induced apoptosis in HNSCC cells and was more potent than other Akt-mTOR inhibitors.
• CC-223 demonstrated negligible cytotoxicity towards primary human oral epithelial cells.
• CC-223 effectively blocked mTORC1 and mTORC2 activation both in vitro and in vivo.
• Oral administration of CC-223 potently inhibited tumor growth in vivo with well-tolerated doses.

Conclusions:

• CC-223 exhibits potent anti-cancer activity against HNSCC by inhibiting mTOR kinase.
• CC-223 demonstrates a favorable safety profile, being non-cytotoxic to normal oral epithelial cells.
• CC-223 shows translational potential as a therapeutic agent for HNSCC treatment.